Ocular Therapeutix Inc (NASDAQ:OCUL) price on Wednesday, April 30, rose 1.10% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $8.30.
A look at the stock’s price movement, the close in the last trading session was $8.21, moving within a range at $8.12 and $8.395. The beta value (5-Year monthly) was 1.487. Turning to its 52-week performance, $11.77 and $4.62 were the 52-week high and 52-week low respectively. Overall, OCUL moved 13.23% over the past month.
Ocular Therapeutix Inc’s market cap currently stands at around $1.32 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-02.
Analysts have a consensus estimate of 16.95M for the company’s revenue for the quarter, with a low and high estimate of 16.1M and 17.9M respectively. The average forecast suggests up to a 14.71% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 70.84M, representing a 11.16% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that OCUL is a 50% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 3 recommend OCUL as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
OCUL’s current price about 13.26% and 12.95% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 60.74, while 7-day volatility ratio is 4.33% and 9.29% in the 30-day chart. Further, Ocular Therapeutix Inc (OCUL) has a beta value of 1.50, and an average true range (ATR) of 0.52. Analysts have given the company’s stock an average 52-week price target of $19, forecast between a low of $19 and high of $19. Looking at the price targets, the low is -128.92% off current price level while to achieve the yearly target high, price needs to move -128.92%. Nonetheless, investors will most likely welcome a -128.92% jump to $19 which is the analysts’ median price.
If we refocus on Ocular Therapeutix Inc (NASDAQ:OCUL), historical trading data shows that trading volumes averaged 1.33 over the past 10 days and 1.52 million over the past 3 months. The company’s latest data on shares outstanding shows there are 157.75 million shares.
The 15.79% of Ocular Therapeutix Inc’s shares are in the hands of company insiders while institutional holders own 73.21% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 14.1 million on 2025-04-15, giving us a short ratio of 7.69. The data shows that as of 2025-04-15 short interest in Ocular Therapeutix Inc (OCUL) stood at 889.99994 of shares outstanding, with shares short rising to 12.83 million registered in 2025-03-14. Current price change has pushed the stock -2.81% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the OCUL stock continues to rise going into the next quarter.
